Postchemotherapy residual masses in advanced seminoma: current management and outcomes

References

• Steele GS, Richie JP. Current role of retroperitoneal lymph node dissection in testicular cancer. Oncology 11, 717–737 (1997).
   PubMedGoogle Scholar
• Gospodarwicz MK, Sturgeon JF, Jewett MA. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin. Oncol. 25, 160–173 (1998).
   PubMedGoogle Scholar
• Fossa SD, Horwich A, Russell JM et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J. Clin. Oncol. 17, 1146 (1999).
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst. 89, 1429–1439 (1997).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Birch R, Williams SD et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J. Clin. Oncol. 5, 1212–1220 (1987).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Williams SD, Einhorn LH. Status of chemotherapy for testis cancer. Urol. Clin. North Am. 14, 713–720 (1987).
   PubMedGoogle Scholar
• Herr HW, Sheinfeld J, Puc HS et al. Surgery for a post-chemotherapy residual mass in seminoma. J. Urol. 157, 860–862 (1997).
   PubMed Web of Science ®Google Scholar
• Friedman EL, Garnick MB, Stomper PC et al. Therapeutic guidelines and results in advanced seminoma. J. Clin. Oncol. 3, 1325–1332 (1985).
   PubMed Web of Science ®Google Scholar
• Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br. J. Cancer 52, 7–13 (1985).
   PubMed Web of Science ®Google Scholar
• Horwich A, Dearnaley DP, Duchesne GM et al. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J. Clin. Oncol. 7, 1150–1156 (1989).
   PubMed Web of Science ®Google Scholar
• Flechon A, Bompas E, Biron P et al. Management of post-chemotherapy residual masses in advanced seminoma. J. Urol. 168, 1975–1979 (2002).
   PubMedGoogle Scholar
• Stomper PC, Jochelson MS, Friedman EL, Garnick MB, Richie JP. CT evaluation of advanced seminoma treated with chemotherapy. AJR Am. J. Roentgenol 146, 745–748 (1986).
   PubMedGoogle Scholar
• Schultz SM, Einhorn LH, Conces DJ Jr. et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J. Clin. Oncol. 7, 1497–1503 (1989).
   PubMed Web of Science ®Google Scholar
• Vuky J, Tickoo SK, Sheinfeld J et al. Salvage chemotherapy for patients with advanced pure seminoma. J. Clin. Oncol. 20, 297–301 (2002).
   PubMed Web of Science ®Google Scholar
• Horwich A, Paluchowska B, Norman A et al. Residual mass following chemotherapy of seminoma. Ann. Oncol. 8, 37–40 (1997).
   PubMed Web of Science ®Google Scholar
• Fossa SD, Kullmann G, Lien HH et al. Chemotherapy of advanced seminoma: clinical significance of radiological findings before and after treatment. Br. J. Urol. 64, 530–534 (1989).
   PubMedGoogle Scholar
• Fossa SD, Droz JP, Stoter G et al. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br. J. Cancer 71, 619–624 (1995).
   PubMed Web of Science ®Google Scholar
• Ellison MF, Mostofi FK, Flanigan RC. Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J. Urol. 140, 618–620 (1988).
   PubMedGoogle Scholar
• Mosharafa AA, Foster RS, Leibovich BC et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J. Urol. 169, 2126–2128 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly R, Skinner D, Yellin AE et al. En bloc aortic resection for bulky metastatic germ cell tumors. J. Urol. 153, 1849–1851 (1995).
   PubMedGoogle Scholar
• Spitz A, Wilson TG, Kawachi MH et al. Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. J. Urol. 158, 1813–1818 (1997).
   PubMedGoogle Scholar
• Herr HW, Bosl G. Residual mass after chemotherapy for seminoma: changing concepts of management. J. Urol. 137, 1234–1235 (1987).
   PubMedGoogle Scholar
• Motzer R, Bosl G, Heelan R et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J. Clin. Oncol. 5, 1064–1070 (1987).
   PubMed Web of Science ®Google Scholar
• Puc HS, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J. Clin. Oncol. 14, 454–460 (1996).
   PubMed Web of Science ®Google Scholar
• Ravi R, Ong J, Oliver RT et al. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int. 83, 649–653 (1999).
   PubMedGoogle Scholar
• Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol. Int. 57, 38–42 (1996).
   PubMed Web of Science ®Google Scholar
• Kamat MR, Kulkarni JN, Tongaonkar HB et al. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J. Surg. Oncol. 51, 65–67 (1992).
   PubMed Web of Science ®Google Scholar
• Marks LB, Anscher MS, Shipley WU. The role of radiation therapy in the treatment of testicular germ cell tumors. Hematol. Oncol. Clin. North Am. 5, 1143–1172 (1991).
   PubMedGoogle Scholar
• Duchesne GM, Stenning SP, Aass N et al. Radiotherapy after chemotherapy for metastatic seminoma-a diminishing role. MRC Testicular Tumour Working Party. Eur. J. Cancer 33, 829–835 (1997).
   PubMed Web of Science ®Google Scholar
• Ravi R, Vasanthan A. Intraoperative irradiation: another option for the treatment of > or = 3 cm residual mass following chemotherapy for advanced testicular seminoma. Urol. Int. 55, 137–140 (1995).
   PubMedGoogle Scholar
• Miller KD, Loehrer PJ, Gonin R et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J. Clin. Oncol. 15, 1427–1431 (1997).
   PubMed Web of Science ®Google Scholar
• Warren GP, Einhorn LH. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma. J. Clin. Oncol. 13, 2784–2788 (1995).
   PubMedGoogle Scholar
• Ganjoo KN, Chan RJ, Sharma M et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J. Clin. Oncol. 17, 3457–3460 (1999).
   PubMed Web of Science ®Google Scholar
• De Santis M, Becherer A, Bokemeyer C et al. 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol. 22, 1034–1039 (2004).
   PubMed Web of Science ®Google Scholar
• De Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2–18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J. Clin. Oncol. 19, 3740–3744 (2001).
   PubMedGoogle Scholar
• Becherer A, De Santis M, Karanikas G et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur. J. Radiol. 54, 284–288 (2005).
   PubMed Web of Science ®Google Scholar
• McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J. Clin. Oncol. 15, 2559–2563 (1997).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J. Clin. Oncol. 18, 2413–2418 (2000).
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Co-operative Oncology Group. J. Clin. Oncol. 20, 1859–1863 (2002).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 20, 2031–2037 (2002).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Kollmannsberger C, Stenning S et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br. J. Cancer 91, 683–687 (2004).
   PubMed Web of Science ®Google Scholar